Evaluation of a Fast Protocol for Staging Lymphoma Patients with Integrated PET/MRI

Abstract

BackgroundThe aim of this study was to assess the applicability of a fast MR-protocol for whole-body staging of lymphoma patients using an integrated PET/MR system.MethodsA total of 48 consecutive lymphoma patients underwent 52 clinically indicated PET/CT and subsequent PET/MRI examinations with the use of 18F-FDG. For PET/MR imaging, a fast whole-body MR-protocol was implemented. A radiologist and a nuclear medicine physician interpreted MRI and PET/MRI datasets in consensus and were instructed to identify manifestations of lymphoma on a site-specific analysis. The accuracy for the identification of active lymphoma disease was calculated and the tumor stage for each examination was determined. Furthermore, radiation doses derived from administered tracer activities and CT protocol parameters were estimated and the mean scan duration of PET/CT and PET/MR imaging was determined. Statistical analysis was performed to compare the diagnostic performance of PET/MRI and MRI alone. The results of PET/CT imaging, all available histopathological samples as well as results of prior examinations and follow-up imaging were used for the determination of the reference standard.ResultsActive lymphoma disease was present in 28/52 examinations. PET/MRI revealed higher values of diagnostic accuracy for the identification of active lymphoma disease in those 52 examinations in comparison to MRI, however, results of the two ratings did not differ significantly. On a site specific analysis, PET/MRI showed a significantly higher accuracy for the identification of nodal manifestation of lymphoma (p<0.05) if compared to MRI, whereas ratings for extranodal regions did not reveal a significant difference. In addition, PET/MRI enabled correct identification of lymphoma stage in a higher percentage of patients than MRI (94% vs. 83%). Furthermore, SUVs derived from PET/MRI were significantly higher than in PET/CT, however, there was a strong positive correlation between SUVmax and SUVmean of the two imaging modalities (R = 0.91 p<0.001 and R = 0.87, p<0.001). Average scan duration of whole-body PET/CT and PET/MRI examinations amounted to 17.3±1.9 min and 27.8±3.7 min, respectively. Estimated mean effective-dose for whole-body PET/CT scans were 64.4% higher than for PET/MRI.ConclusionsOur results demonstrate the usefulness of 18F-FDG PET data as a valuable additive to MRI for a more accurate evaluation of patients with lymphomas. With regard to patient comfort related to scan duration and a markedly reduced radiation exposure, fast PET/MRI may serve as a powerful alternative to PET/CT for a diagnostic workup of lymphoma patients.

18F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis

“…With tumor-induced paraneoplastic limbic encephalitis being one of the three major causes of limbic encephalitis, patients suspected of LE commonly undergo whole-body imaging to rule out underlying oncologic diseases. As reported in a vast amount of previous publications integrated PET/MRI facilitates a highly valuable platform for whole-body staging [15,[41][42][43]. In our study, an underlying oncologic disease could be ruled out in 18 patients, while one patient with rectal cancer could be correctly identified, and one suspicious subcutaneous lesion in another patient was false positive in MRI as well as PET.…”

The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG)

“…Further development in MRI, such as whole-body diffusion-weighted imaging with background body signal suppression and functional MRI, are showing promise in improving lymphoma characterization. [55][56][57][58]…”

Whole-Body [18F]-FDG-PET/MRI for Oncology: A Consensus Recommendation

“…This workflow is based on a 4-min/bed acquisition that comprises diffusion-weighted imaging (DWI) in addition to the above-mentioned sequences listed in the ultra-fast algorithm (▶ Fig. 2) [62,63]. The additional diffusion-weighted sequence offers comple-mentary tissue information to PET and may be applied as a "search" sequence as it is considered useful particularly in the detection of small lesions, e. g., liver metastases that may be too small to be picked up by PET.…”